Patents by Inventor Nina MOKER

Nina MOKER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11957715
    Abstract: The present invention discloses an in-vitro method for transferring biological material into activated NK cells with a pseudotyped retroviral vector particle or a virus-like particle thereof, comprising the steps a) activation of NK cells, and b) addition of said pseudotyped retroviral vector particle or virus-like particle thereof to said activated NK cells, wherein said pseudotyped retroviral vector particle or virus-like particle thereof comprises a modified baboon endogenous retrovirus (BaEV) envelope glycoprotein that is able of binding to and fusing with a hematopoietic cell membrane, thereby transferring biological material into said activated NK cells. Preferentially, the activating of NK cells is performed by the addition of a IL-1 family cytokine to the NK cells.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: April 16, 2024
    Assignee: MILTENYI BIOTEC B.V. & CO. KG
    Inventors: Rafijul Bari, Markus Granzin, Wing Leung, Nina Moker, Volker Huppert
  • Patent number: 11524998
    Abstract: The present disclosure provides anti-BTC antibodies, methods of producing said antibodies, pharmaceutical compositions comprising said antibodies, and methods of using said antibodies. The present disclosure also provides multi-specific binding molecules, e.g., bispecific antibodies, comprising a BTC binding moiety and an anti-VEGF binding moiety.
    Type: Grant
    Filed: July 14, 2021
    Date of Patent: December 13, 2022
    Assignee: NOVARTIS AG
    Inventors: Chad Eric Bigelow, Ana Maria Carrion, James Edgar Chastain, Kirk Lee Clark, Bijan Alexandre Etemad-Gilbertson, Joy Gispati Ghosh, Shawn Michael Hanks, Nicole Haubst, Ganesh Rajan Iyer, Nina Moker, Andrew Anh Nguyen, Stephen Hedrick Poor, Yubin Qiu, Nalini Velamur Rangaswamy, Michael Stefanidakis, Engin Toksoz, Michael Zbigniew Twarog
  • Publication number: 20220356236
    Abstract: The present disclosure provides anti-BTC antibodies, methods of producing said antibodies, pharmaceutical compositions comprising said antibodies, and methods of using said antibodies. The present disclosure also provides multi-specific binding molecules, e.g., bispecific antibodies, comprising a BTC binding moiety and an anti-VEGF binding moiety.
    Type: Application
    Filed: June 30, 2022
    Publication date: November 10, 2022
    Inventors: Chad Eric BIGELOW, Ana Maria CARRION, James Edgar CHASTAIN, Kirk Lee CLARK, Bijan Alexandre ETEMAD-GILBERTSON, Joy Gispati GHOSH, Shawn Michael HANKS, Nicole HAUBST, Ganesh Rajan IYER, Nina MOKER, Andrew Anh NGUYEN, Stephen Hendrick POOR, Yubin QIU, Nalini Velamur RANGASWAMY, Michael STEFANIDAKIS, Engin TOKSOZ, Michael Zbigniew TWAROG
  • Publication number: 20220348646
    Abstract: The present disclosure provides anti-BTC antibodies, methods of producing said antibodies, pharmaceutical compositions comprising said antibodies, and methods of using said antibodies. The present disclosure also provides multi-specific binding molecules, e.g., bispecific antibodies, comprising a BTC binding moiety and an anti-VEGF binding moiety.
    Type: Application
    Filed: June 30, 2022
    Publication date: November 3, 2022
    Inventors: Chad Eric BIGELOW, Ana Maria CARRION, James Edgar CHASTAIN, Kirk Lee CLARK, Bijan Alexandre ETEMAD-GILBERTSON, Joy Gispati GHOSH, Shawn Michael HANKS, Nicole HAUBST, Ganesh Rajan IYER, Nina MOKER, Andrew Anh NGUYEN, Stephen Hendrick POOR, Yubin QIU, Nalini Velamur RANGASWAMY, Michael STEFANIDAKIS, Engin TOKSOZ, Michael Zbigniew TWAROG
  • Publication number: 20220025032
    Abstract: The present disclosure provides anti-BTC antibodies, methods of producing said antibodies, pharmaceutical compositions comprising said antibodies, and methods of using said antibodies. The present disclosure also provides multi-specific binding molecules, e.g., bispecific antibodies, comprising a BTC binding moiety and an anti-VEGF binding moiety.
    Type: Application
    Filed: July 14, 2021
    Publication date: January 27, 2022
    Inventors: Chad Eric BIGELOW, Ana Maria CARRION, James Edgar CHASTAIN, Kirk Lee CLARK, Bijan Alexandre ETEMAD-GILBERTSON, Joy Gispati GHOSH, Shawn Michael HANKS, Nicole HAUBST, Ganesh Rajan IYER, Nina MOKER, Andrew Anh NGUYEN, Stephen Hendrick POOR, Yubin QIU, Nalini Velamur RANGASWAMY, Michael STEFANIDAKIS, Engin TOKSOZ, Michael Zbigniew TWAROG
  • Publication number: 20200390812
    Abstract: The present invention discloses an in-vitro method for transferring biological material into activated NK cells with a pseudotyped retroviral vector particle or a virus-like particle thereof, comprising the steps a) activation of NK cells, and b) addition of said pseudotyped retroviral vector particle or virus-like particle thereof to said activated NK cells, wherein said pseudotyped retroviral vector particle or virus-like particle thereof comprises a modified baboon endogenous retrovirus (BaEV) envelope glycoprotein that is able of binding to and fusing with a hematopoietic cell membrane, thereby transferring biological material into said activated NK cells. Preferentially, the activating of NK cells is performed by the addition of a IL-1 family cytokine to the NK cells.
    Type: Application
    Filed: December 19, 2018
    Publication date: December 17, 2020
    Applicant: MILTENYI BIOTEC B.V. & CO. KG
    Inventors: Rafijul BARI, Markus GRANZIN, Wing LEUNG, Nina MOKER, Volker HUPPERT